iRhythm Technologies Highlights Revenue Growth and Expansion

Irhythm Technologies ( (IRTC) ) just unveiled an update.

On November 12, 2025, iRhythm Technologies issued an investor presentation highlighting a 26% year-to-date revenue increase compared to 2024, driven by significant commercial adoption and market expansion. The company is advancing its international reach and product offerings, including a new 510(k) submission for the Zio MCT with extended wear and AI capabilities. Despite facing challenges such as an FDA warning letter and a DOJ investigation, iRhythm is on track to achieve free cash flow positivity for the first time in its history, indicating strong operational and financial progress.

The most recent analyst rating on (IRTC) stock is a Buy with a $215.00 price target. To see the full list of analyst forecasts on Irhythm Technologies stock, see the IRTC Stock Forecast page.

Spark’s Take on IRTC Stock

According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.

Irhythm Technologies’ overall stock score is driven by strong earnings call performance and positive technical indicators. However, significant financial performance challenges, particularly high leverage and negative profitability, weigh heavily on the score. The valuation is also a concern due to the negative P/E ratio.

To see Spark’s full report on IRTC stock, click here.

More about Irhythm Technologies

iRhythm Technologies, Inc. operates in the healthcare industry, focusing on providing ambulatory cardiac monitoring solutions. The company is known for its Zio platform, which offers extended wear cardiac monitors and aims to improve patient outcomes through advanced data analytics and AI capabilities. iRhythm is expanding its market presence internationally, targeting opportunities in the EU and Asia Pacific regions.

Average Trading Volume: 406,841

Technical Sentiment Signal: Buy

Current Market Cap: $5.68B

Find detailed analytics on IRTC stock on TipRanks’ Stock Analysis page.